HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR Expert Panel Wants Nano Data For Ingredient Reviews

Executive Summary

Are nanoparticle data necessarily relevant to every ingredient assessment undertaken by Cosmetic Ingredient Review’s independent expert panel? Let us be the judge of that, the panel said on 27 September at its 162nd meeting.

You may also be interested in...



CIR Expert Panel’s September Safety Findings, Final 2023 Priorities

Cosmetic Ingredient Review’s panel of independent experts will be highly focused on botanical ingredients in 2023 – a sign of the times, it says. At its September meeting, the panel finalized six ingredient safety reports, advanced four tentative reports, and issued an insufficient data announcement for Phenyl-Substituted Methicones.

CIR’s 161st Expert Panel Meeting: Much Ado About Airbrush Cosmetics; Prostaglandins Make 2023 Priorities

Exactly what is in airbrush-delivered cosmetics, and how they are used by consumers, are not well understood by Cosmetic Ingredient Review, its expert panel, or the US FDA. At their June meeting, CIR’s independent experts debated who should be responsible for assessing airbrush cosmetics and how safety unknowns should be communicated.

CIR Panel Throws Up Hands At Airbrush Ingredient Safety, Defers To FDA On Eyelash ‘Enhancers’

The US-based Cosmetic Ingredient Review’s independent experts finalized four ingredient safety reports at its 7-8 March meeting, advanced nine tentative assessments, and issued two insufficient data announcements. The panel continues to face challenges in assessing ingredients used in airbrush applications and decided against prioritizing review of eyelash-"enhancing" prostaglandin analogues.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel